Skip to main content
. Author manuscript; available in PMC: 2014 Sep 1.
Published in final edited form as: Oral Oncol. 2013 Jul 23;49(9):893–902. doi: 10.1016/j.oraloncology.2013.06.011

Figure 4. Antitumor activity of combination treatment against orthotopic FaDu tumors.

Figure 4

(A) Bioluminescent images of control and VDA-treated mice bearing orthotopic FaDu tumors at baseline, 1hr and 24hrs post VDA treatment (DMXAA 25mg/kg × 1 dose) (n=3 mice per group). (B) Reported flux values over time for control and VDA treated mice. A significant increase in flux was observed at 1 hour (p<0.001) followed by a reduction at 24 hours hours post VDA treatment (p<0.001). (C) T2-weighted images of mice bearing orthotopic FaDu tumors (arrows) acquired once a week during the eight week monitoring period. Significant tumor growth inhibition following combination treatment compared to single agent treatment and controls. Kaplan-Meier plots showing progression free survival (D) and overall survival (E) of animals from all four groups. Combination treatment resulted in a significant increase in OS of animals compared to VDA alone (p<0.001) and chemotherapy alone (p<0.05) (n=5-9 mice per group).